RFG Advisory LLC Boosts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

RFG Advisory LLC raised its stake in Edwards Lifesciences Co. (NYSE:EW) by 7.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,784 shares of the medical research company’s stock after purchasing an additional 521 shares during the period. RFG Advisory LLC’s holdings in Edwards Lifesciences were worth $744,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Pathway Financial Advisors LLC acquired a new stake in Edwards Lifesciences in the first quarter worth about $228,000. Inscription Capital LLC acquired a new stake in Edwards Lifesciences in the first quarter worth about $2,233,000. Apella Capital LLC acquired a new stake in Edwards Lifesciences in the first quarter worth about $202,000. Lantz Financial LLC acquired a new stake in Edwards Lifesciences in the first quarter worth about $247,000. Finally, Wedmont Private Capital boosted its holdings in Edwards Lifesciences by 5.2% in the first quarter. Wedmont Private Capital now owns 8,189 shares of the medical research company’s stock worth $762,000 after acquiring an additional 405 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, CEO Bernard J. Zovighian purchased 580 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the transaction, the chief executive officer now owns 3,268 shares of the company’s stock, valued at $280,198.32. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Bernard J. Zovighian acquired 580 shares of the stock in a transaction on Monday, May 6th. The shares were bought at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $94.89, for a total value of $688,426.95. Following the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at approximately $1,809,931.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 127,104 shares of company stock worth $11,267,464. 1.29% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on EW shares. Stifel Nicolaus raised their price target on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday, April 26th. StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Tuesday, June 18th. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Mizuho lifted their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Finally, Piper Sandler lifted their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $95.06.

Edwards Lifesciences Stock Up 2.3 %

Edwards Lifesciences stock opened at $90.90 on Monday. The stock has a market capitalization of $54.78 billion, a PE ratio of 39.18, a price-to-earnings-growth ratio of 3.25 and a beta of 1.11. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The business has a 50 day simple moving average of $87.46 and a 200-day simple moving average of $84.64. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.